Navigation Links
Acorda Therapeutics to Host Analyst and Investor Reception

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today announced that Dr. Lauren Krupp, Professor of Neurology at Stony Brook University, will present data from Acorda's Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at their analyst and investor reception on May 2, 2007. This reception will follow a presentation of this data at the American Academy of Neurology (AAN) annual meeting.

Dr. Krupp's presentation will begin at 7:00 pm Eastern Time (ET) and will be able via a live webcast at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c= 194451&eventID=1529938

Archived versions of the webcast will be available for 90 days on our website at http://phx.corporate-ir.net/phoenix.zhtml?c= 194451&p=irol-irhome. (Due to their length, these URLs may need to be copied/pasted into your Internet browser's address field. Remove extra spaces if they exist.)

The platform presentation of the Phase 3 clinical trial of Fampridine-SR data at the AAN meeting will take place on May 2, 2007 at 4:15 pm ET. This abstract was selected to be part of the Scientific Highlights program, which spotlights the top five percent of the more than 1600 abstracts accepted for presentation at this meeting. This presentation was also selected for a second highlights session, Multiple Sclerosis Scientific Topic Highlights, to be presented on May 3, 2007 at 7:00 pm ET. The AAN meeting will take place at the Hynes Convention Center in Boston, MA.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause act ual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Contact

Acorda Therapeutics
Erica Wishner, 914-347-4300 ext. 162
ewishner@acorda.com


'"/>




Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Our bodies are bombarded daily by environmental and lifestyle ... these stressors is to adopt a more healthful diet, but too many people think ... certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses ... Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... Toronto, ON (PRWEB) , ... April 29, 2016 ... ... GlutenFreeCoupons.ca and the Canadian Celiac Association (CCA), is pleased to announce the launch ... about gluten-free products, nutritional articles, recipes, and more. The purpose of the ...
Breaking Medicine News(10 mins):